Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Post-trial Access Roll-over Study of Ribociclib in Metastatic Breast Cancer
NCT05161195Phase 4Active, not recruiting
- Sponsor
- Novartis
- Start
- Jul 2022
- Primary completion
- Jun 2030
- Modality
- Small Molecules
- Countries
- 22
01
Overview
Phase 4, open-label, single-arm trial of ribociclib in breast cancer, sponsored by Novartis. Primary endpoint: Treatment-emergent adverse events up to 8 years. Started Jul 2022; status: active, not recruiting.
02
Drugs
ribociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05161195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05161195.